Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.38 and traded as high as $1.50. Atossa Therapeutics shares last traded at $1.50, with a volume of 704,919 shares trading hands.
Analyst Ratings Changes
Several brokerages have recently weighed in on ATOS. StockNews.com downgraded shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday. Ascendiant Capital Markets raised their price objective on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a "buy" rating in a research note on Wednesday, September 11th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $6.00 target price on shares of Atossa Therapeutics in a research note on Thursday, October 31st.
Check Out Our Latest Stock Analysis on Atossa Therapeutics
Atossa Therapeutics Stock Performance
The firm has a market capitalization of $188.64 million, a P/E ratio of -7.14 and a beta of 1.23. The stock's 50 day simple moving average is $1.44 and its 200 day simple moving average is $1.38.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts anticipate that Atossa Therapeutics, Inc. will post -0.22 earnings per share for the current year.
Hedge Funds Weigh In On Atossa Therapeutics
Several institutional investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new position in Atossa Therapeutics during the 2nd quarter worth about $29,000. SG Americas Securities LLC lifted its holdings in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock worth $64,000 after buying an additional 30,037 shares during the period. Cetera Advisors LLC bought a new stake in Atossa Therapeutics during the 1st quarter valued at $72,000. Vanguard Group Inc. increased its holdings in shares of Atossa Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company's stock valued at $10,357,000 after acquiring an additional 78,269 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Atossa Therapeutics in the 1st quarter valued at $151,000. Hedge funds and other institutional investors own 12.74% of the company's stock.
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Featured Stories
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
